For example, serum NfL levels and amyloid beta peptide levels are elevated from baseline several years prior to the clinical presentation of multiple sclerosis (MS) and AD, respectively (Bjornevik et al., 2020; Stocker et al., 2020). This evidence concerns the gene NEFL and Alzheimer disease.